The Ridgewood Blog Brings a Free Market Laissez-faire Point of View to Local, New Jersey State and National Issues.
the staff of the Ridgewood blog
Ridgewood NJ, Peppr, the interactive online culinary experience created by New Jersey natives Chopped Champion Chef Andrew Riccatelli (Executive Chef of Buddha-Bar), Daniel Fiorica and Alexia Merlo, connects people nationally with Food Network Chopped Champions who provide step-by-step instructions on how to create signature dishes in your own kitchen.
the staff of the Ridgewood blog
New Brunswick NJ, Rutgers University will require the COVID-19 vaccine for students who are enrolled for the 2021 fall semester.
Assurances from the federal government that vaccines will be available for all Americans by the end of May and assessments by public health experts prompted university leaders to adjust the vaccine requirements for the fall semester.
Continue reading Rutgers University to Require COVID-19 Vaccine for Students
the staff of the Ridgewood blog
New Brunswick NJ, Rutgers researchers have designed a new rapid test that can detect all three of the rapidly spreading variants of the coronavirus in a little over one hour – much shorter than the three to five days required by current tests, which can also be more technically difficult and expensive to perform.
the staff of the Ridgewood blog
New Brunswick NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.
Continue reading Johnson & Johnson single-shot COVID-19 vaccine Gets the Green Light from FDA
the staff of the Ridgewood blog
New Brunswick NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial.
the staff of the Ridgewood blog
New Brunswick NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company’s EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately following authorization.
the staff of the Ridgewood blog
New Brunswick NJ, Rutgers University, inspired by the color-changing skin of cuttlefish, octopuses and squids, Rutgers engineers have created a 3D-printed smart gel that changes shape when exposed to light, becomes “artificial muscle” and may lead to new military camouflage, soft robotics and flexible displays.
the staff of the Ridgewood blog
New Brunswick NJ, Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s phase 3 clinical research study to evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate.
the satff of the Ridgewood blog
New Brunswick NJ, while polling has produced less than stellar results in the last 20 years , so take this with a grain of salt , according a recent Rutgers-Eagleton Poll between 36 percent and 47 percent of New Jerseyans say they will “probably” or “definitely” not get vaccinated against COVID-19, with response rates varying depending on how the question is asked, according to the latest Rutgers-Eagleton Poll.
the staff of the Ridgewood blog
NEW BRUNSWICK NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online imminently. Based on these results and following discussions with the U.S. Food and Drug Administration (FDA), ENSEMBLE will enroll up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19.
the staff of the Ridgewood blog
West Orange NJ, RWJBarnabas Health is proud to have been a participant in one of the Gilead trials to assess antiviral Remdesivir as a treatment for patients with severe COVID-19. Gilead recently announced promising top line results that show similar efficacy with 5- and 10- day dosing durations of the drug.
the staff of the Ridgewood blog
New Brunswick NJ,Rutgers University announced today that it has launched the nation’s largest prospective study of health care workers exposed to COVID-19. The study includes a series of clinical trials that will explore new drug treatments, antibody testing, and long-term health tracking in the hope of providing insight into how to treat the disease and prevent its spread.
the staff of the Ridgewood blog
NEW BRUNSWICK NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.
David Alland, director of the Public Health Institute at Rutgers New Jersey Medical School, led the research team that assessed a late test prototype.
John Emerson
the staff of the Ridgewood blog
New Brunswick NJ, A Rutgers research team has completed the first evaluation of a new rapid COVID-19 test given emergency approval by the FDA. The test, developed by CEPHEID, a U.S. molecular diagnostics company, is fast and easy to perform without the need for a centralized laboratory. The company said the test would be available next week.
Continue reading Rutgers Researchers Evaluate New Rapid COVID-19 Test
New Brunswick NJ, A New Brunswick, New Jersey, man was sentenced today to life plus 20 years in prison for his violent role in a racketeering conspiracy involving multiple brothels that employed illegal aliens throughout New Jersey, U.S. Attorney Craig Carpenito announced.
Wilmer Chavez Romero, a/k/a “Charmin,” 29, was previously convicted of all eight counts of an indictment charging him with one count each of racketeering, racketeering conspiracy, assault with a dangerous weapon in aid of racketeering, and conspiracy to harbor aliens; two counts of using a firearm for a violent crime; and two counts of murder in aid of racketeering. He was convicted following a two and a half-week trial before U.S. District Judge William H. Walls, who imposed the sentence today in Newark federal court.
Continue reading Enforcer for NJ Sex Trafficking Ring Sentenced To Life Plus 20 Years On Racketeering, Murder, And Weapon Charges
